Beijing BeiLu Pharmaceutical decided to end its agomelatine development project. The company said the SFDA refused to authorize a clinical trial of agomelatine, an antidepressant drug, saying the IND filing did not prove the drug was effective. BeiLu explained that a new application for a clinical trial would take three years, which it feels would cause the company to miss the most opportune launch window for the product. More details....

Stock Symbol: (SHE: 300016)     Share this with colleagues: